Navigation Links
Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance

Affymetrix Inc. (Nasdaq: AFFX - News) and Karolinska Institutet announced today that they have entered into a strategic alliance designed to improve healthcare by accelerating the translation of basic genetic research into tools for better diagnosis, prognosis, and treatment.

During the next five years the projects include genetic analyses and measurement of gene expression in patients with atherosclerosis, breast cancer, rheumatoid arthritis, asthma and dyslexia. These diseases affect a large number of patients worldwide. Systematic use of the genomic information obtained will enable development of new and better clinical methods and drugs hereby reducing mortality and improving quality of life for patients suffering from these diseases.

The Karolinska Institutet/Affymetrix Translational medicine research projects will use sufficiently large sample sizes to establish true clinical relevance of both gene expression and DNA sequence variation in key areas of unmet medical needs.

"Today we have access to a very broad range of population-based clinical materials and data, that we want to study in order to understand the importance of genetic factors for emergence and treatment of various diseases. The agreement enables us to perform these studies at an acceptable cost and we will also get access to new technology at an early stage. Our expectation is that this cooperation will help us to improve peoples health", said Professor Jan Carlstedt-Duke, dean of research at Karolinska Institutet.

"To improve human health, we need to shift the healthcare paradigm from diagnosing and treating existing diseases, to being able to predicting disease susceptibility and an individual's response to drugs," said Patrick Kelly, European Site Manager and Vice President, Affymetrix. "This is what personalized medicine is all about -- enabling clinicians to detect diseases earlier and manage them more effectively. We are excited about the potential of this ag
'"/>

Source:Affymetrix


Page: 1 2 3

Related biology news :

1. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
2. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
3. Affymetrix and Stratagene Announce Strategic Software Alliance
4. Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences
5. Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX
6. Affymetrix and bioMerieux Extend Their Agreement on GeneChip(R) Technology to Breast Cancer Diagnostics
7. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
8. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
9. Affymetrix 500K array used to identify memory gene
10. FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
11. Ariadne Genomics Announces the Release of PathwayStudio?Central, Client-Server Software for Biological Pathway Analysis

Post Your Comments:
(Date:11/23/2009)... Iowa - The only swine vaccine available for the H...infected with the virus. The vaccination marks the...diagnosed with the pandemic flu., Iowa State Uni..., developed the vaccine this summer and has been s...a, Kansas and Illinois for several weeks., The l...
(Date:11/23/2009)...GN, Ill. Two new studies reveal in unprecedented ...ules to assemble new proteins and guide them towar...es used molecular dynamics flexible fitting (MDFF)...wo prominent molecular partners. , The first st...iences , concerns the intimate signaling between t...
(Date:11/23/2009)...ional Institute of General Medical Sciences (NIGMS..., is investing $42.3 million for grants in scienti...O)." NIH developed the GO grant program to stimula... provided by the American Recovery and Reinvestmen...ects that promise to have a significant impact on ...
Breaking Biology News(10 mins):Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3Platelet Rich Plasma 3A Does It Work 3F 58657 1Platelet Rich Plasma 3A Does It Work 3F 58657 2Platelet Rich Plasma 3A Does It Work 3F 58657 3Platelet Rich Plasma 3A Does It Work 3F 58657 4DST Systems Inc Announces Exchange Transaction Involving 4 125 25 Series A Convertible Senior Debentures 58653 1DST Systems Inc Announces Exchange Transaction Involving 4 125 25 Series A Convertible Senior Debentures 58653 2Medicago begins human clinical testing with its avian flu pandemic vaccine 14315 1Medicago begins human clinical testing with its avian flu pandemic vaccine 14315 2
...urned on to target and destroy foreign infectious ...n, it is just as important to turn the immune syst.... The fruit fly Drosophila has served as a good mo..., pointing to conserved pathways and mechanisms. R...more subtly regulated and produces a wider range o...
...ld at the University of Edinburgh, 3-6 September 2... fingers, faeces and flies: food and waterborne pa...s. , Hepatitis E virus (HEV), which can be fatal,...veloping countries but scientists in the Netherlan...e contracting the virus from pork. It is one of fe...
...els in coastal waters interfere with fish reproduc...cientist from The University of Texas at Austin Ma...seasonal low levels of oxygen, known as hypoxia, h...ghout the world over the past few decades, largely...ultural and industrial activities. Hypoxias long-t...
Other Biology News:Society for General Microbiology 161st Meeting, University of Edinburgh 2Low oxygen in coastal waters impairs fish reproduction 2
(Date:11/24/2009)... Health care employment grew by 29,000 jobs in Oc...consistent growth during the U.S. recession. Howev...ble, and health systems are coming closer to havin...st administrators. , (Voc...ntinued growing in October despite the shedding of...
(Date:11/24/2009)...Newswire-Asia/--ShanghaiBiolaxyannouncedthe,Chines...the,investigationalnewdrugapplication(IND)foritsor...lationtotreatdiabetes.ThisIND,approvalallowsBiolax...betesisadisordercharacteristicofhighbloodglucosean...sultinseveremicro-and,macro-vasculardiseases,losso...
(Date:11/24/2009)..., TORONTO,Nov.24/PRNewswire-FirstCall/-HamiltonT...eadingproviderofadvancedlasersystemsandinstruments...dayreportedoperationalandfinancialresultsforthethi...ts,-Revenuewas$1.46millioncomparedwith$1.43millio...with66.1percentinQ3,2008,-Netlossreducedto$148,000...
(Date:11/24/2009)...er24/PRNewswire/--HealthRoboticstodayannounced,tha...lected,investors.ThisrecentlyformedToronto-basedco...Inc.andwillmarket,install,andsupport,HealthRobotic...lutionaryproductofferingsi.v.STATION(TM),i.v.SOFT(...ovideassistanceonan"asneeded,basis"toitsstrategicp...
Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...AN DIEGO, Sept. 10 ADVENTRX Pharmaceuticals,Inc. ...elopment company,focused on commercializing propri...er and infectious diseases, announced today that i... Drug Administration (FDA) regarding its,proposed ...th for ANX-514,(docetaxel emulsion). The FDA has i...
...ompany to Hold a Conference Call Tomorrow (Tuesday...the Clinical Trial, Valley Cottage, NEW YORK, Sep...TLB ; LSE: XTL; TASE: XTL) today announced,the ini...e - a serotonin,and norepinephrine reuptake inhibi...thic pain. Bicifadine is being developed for the ...
...OUTH SAN FRANCISCO, Calif., Sept. 7 Monogram,Bios...t William D. Young, CEO,and Chairman, is scheduled...y Partners, G5: The Growth Conference on Monday, S...a.m. Pacific Time) at the St. Regis,Hotel in San F...oadcast or the subsequent archived,recording, log ...
Other Biology Technology:ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA 2ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA 3ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7Monogram Biosciences to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2
Human Antibody Array I Kit, RayBio L Series 507: RayBio Label-based from Raybiotech, Inc.
Mouse Anti-Human HVEM Cell Surface Staining Monoclonal Antibodies, Allophycocyanin Conjugated, 94801 from R&D Systems
... Osmometer for 10 L sample. Ideal for small volum...iatric, general adult, veterinary and experimental...selected values. Includes built-in printer, keypa...-keeping. Optional barcode scanner available. RS...
Rabbit Anti-Human UCP2 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Biology Products: